

Aura Announces Non-Brokered Private Placement of Up to \$1,500,000

TORONTO, Jan. 07, 2019 -- Aura Health Inc. (the "**Company**" or "**Aura**") (**CSE:BUZZ**) is pleased to announce that it is raising up to \$1,500,000 by way of a non-brokered private placement of units of the Company (each a "**Unit**" and collectively, the "**Units**") at a price of \$0.15 per Unit (the "**Offering**"). Each Unit is comprised of one common share in the capital of the Company (each a "**Common Share**" and collectively, the "**Common Shares**") and one-half of one common share purchase warrant (the "**Warrants**"), exercisable at \$0.25 for a period of 24 months from the date of issuance. The net proceeds from the Offering shall be used for general working capital and to advance the Company's involvement in HolyCanna and CannabiSendak.

In connection with the Offering, the Company expects to (i) pay an aggregate cash commission of 8% of the proceeds placed by subscribers introduced to the Company by finders (the "**Placee**") and (ii) issue that number of non-transferrable finders warrants equal to 8% of the number of Units subscribed to by the Placee (each a "**Finder's Warrant**" and collectively, the "**Finder's Warrants**"). Each Finder's Warrant will be exercisable to purchase one Common Share at an exercise price of \$0.25 for a period of 24 months from the date of issuance.

The Offering is expected to close on or about January 10, 2018 (the "**Closing Date**") and remains subject to approval of the Canadian Securities Exchange. Aura expects that insiders of the Company will participate in the Offering.

The Common Shares comprising the Units and all Common Shares issued upon exercise of the Warrants and the Finder's Warrants will be subject to a hold period of four months plus one day from the Closing Date. The Warrants and the Finder's Warrants will be subject to a hold period of four months plus one day from the Closing Date.

About Aura Health Inc.

Aura is building an international network of vertically integrated cannabis assets. The company holds convertible debt that converts to 54% equity of HolyCanna, a cultivation and nursery license holder in Israel, and has an LOI in place to acquire the majority of CannabiSendak, the builder of a network of high-profile dispensaries in Israel. Aura also owns a 30% interest in four medical marijuana clinics in the U.S. Sun Belt, with an option to increase its interest in three of the clinics to 51%.

For further information, please contact:

Daniel Cohen, CEO Aura Health Inc. (647) 202-1824

David Posner, Chairman Aura Health Inc. (647) 985-6727

Caution Regarding Forward-Looking Information:

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe and to the satisfaction of the relevant regulators, completing the acquisition of the applicable real estate and raising sufficient financing to complete the Company's business strategy. There is no certainty that any of these events will occur. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulation S under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such

offer, solicitation or sale would be unlawful.

Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.